
Sanofi, Regeneron win FDA nod for Dupixent in chronic hives
The Food and Drug Administration on Friday approved a new use for Sanofi and Regeneron’s top-selling immune disease drug Dupixent, clearing the medicine to treat a chronic skin condition that causes hives. The agency OK’d Dupixent for chronic spontaneous …